A review of pharmaceutical and clinical studies of cholesterol-lowering drug PCSK9 inhibitor incsilan
Hypercholesterolemia leads to atherosclerosis,causing a large series of cardiocerebrovascular diseases.As the first drug of lowering low-density lipoprotein cholesterol through siRNA therapy approved by the US Food and Drug Administration in 2021,inclisiran has been a promising treatment for dyslipidemia due to it potent lipid-lowering effect and excellent safety.This review summarized the latest researches on the mechanism of action,pharmacokinetic properties,efficacy and safety of inclisiran.Also it briefly explained its unique clinical dosing method and provided reference for its proper clinical use.
inclisiranProprotein convertase subtilisin/kexin type 9 inhibitorssiRNA therapylow-density lipoprotein cholesterol
NETL
NSTL
万方数据
